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(HR, 0.67). In women, the mortality benefit of ICD implant
was not statistically significant at 22% (HR, 0.78).
Conclusions: ICD therapy may confer a lower survival benefit
in women.
Perspective: The confidence interval for the mortality HR in
this study was wide, suggesting heterogeneity exists amongst
the individual trial results, which raises caution when inter-
preting overall meta-analysis mortality. Women appeared to
have lower rates of appropriate ICD interventions, which
may support a lower survival benefit following ICD implant.
If valid, this begs the question of whether differences are
due to the nature of cardiomyopathy and arrhythmogenesis
in women or ICD therapy itself.   
Summary written by: Jennifer Cowger, MD
QT Dynamics Early After Exercise as a Predictor of
Mortality
Johnson NP, Holly TA, Goldberger JJ.
Heart Rhythm 2010;7:1077–1084.
Study Question: Is the response of the QT interval to a slow-
ing heart rate (HR) post-exercise an independent predictor
of mortality?  
Methods: This was a retrospective study of 2,994 patients
(mean age 56 years) who underwent an exercise treadmill
test (ETT). The QT and RR intervals during recovery were
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Gender Differences in Clinical Outcome and
Primary Prevention Defibrillator Benefit in Patients
With Severe Left Ventricular Dysfunction: A
Systematic Review and Meta-Analysis
Santangeli P, Pelargonio G, Dello Russo A, et al.
Heart Rhythm 2010;7:876–882.
Study Question: Do women sustain the same benefit as men
following implantable cardioverter-defibrillator (ICD)
implant for primary prevention in cardiomyopathy?
Methods: A meta-analysis was conducted of published primary
prevention ICD trials in systolic heart failure containing
prospective randomized designs and data on gender-specific
risk. Endpoints included total mortality, appropriate ICD
intervention, and survival benefit of ICD versus placebo.
Results: Of the 3,467 citations retrieved, five published studies
were eligible for inclusion (MADIT-II, MUSTT, SCD-
HeFT, DEFINITE, COMPANION) and each endpoint
had four trials with data satisfactory for use in the analyses.
Of the 7,229 patients, 74% had an ischemic etiology for car-
diomyopathy and 23% were female. Mean follow-up was 41
months. Mortality was similar for women and men (hazard
ratio [HR], 0.96). Women had a lower hazard of appropriate
ICD interventions (HR, 0.63) than men. Men with ICDs
obtained a 33% reduction in mortality compared with placebo
SCANNING THE LITERATURE
Summaries of Key Journal Articles
Kim A. Eagle, MD, Editor-in-Chief, Journal Scan, Ann Arbor, MI
Christopher P. Cannon, MD, Editor-in-Chief, Cardiosource, Boston, MA
William F. Armstrong, MD, Ann Arbor, MI, David S. Bach, MD, Ann Arbor, MI, Ragavendra R.
Baliga, MBBS, Columbus, OH, Anna M. Booher, MD, Ann Arbor, MI, Timothy B. Cotts, MD, 
Ann Arbor, MI, Jennifer Cowger, MD, Ann Arbor, MI, Daniel T. Eitzman, MD, Ann Arbor, MI, 
James B. Froehlich, MD, Ann Arbor, MI, Caren S. Goldberg, MD, Ann Arbor, MI, Hitinder S. Gurm,
MBBS, Ann Arbor, MI, Jennifer C. Hirsch, MD, Ann Arbor, MI, Elizabeth Anne Jackson, MD, 
Ann Arbor, MI, Fred Morady, MD, Ann Arbor, MI, Debabrata Mukherjee, MD, El Paso, TX,
Himanshu J. Patel, MD, Ann Arbor, MI, John E. Rectenwald, MD, MS, Ann Arbor, MI, Melvyn
Rubenfire, MD, Ann Arbor, MI, Associate Editors, Cardiosource
8 607
This relationship is mediated largely through height and
maximum body weight in young adulthood.
Perspective: Prior studies have demonstrated that height and
obesity are risk factors for AF, and this study is confirmatory.
BW is predictive of obesity in adulthood and there is evidence
that excess maternal weight gain during pregnancy is an inde-
pendent predictor of high BW. Therefore, this study provides
indirect evidence that maternal behavior during pregnancy can
influence the later risk of AF in offspring.  
Summary written by: Fred Morady, MD
Endo-Epicardial Ablation of Ventricular
Arrhythmias in the Left Ventricle With the Remote
Magnetic Navigation System and the 3.5-mm Open
Irrigated Magnetic Catheter: Results From a Large
Single-Center Case-Control Series 
Di Biase L, Santangeli P, Astudillo V, et al.
Heart Rhythm 2010;7:1029–1035.
Study Question: How effective is radiofrequency catheter abla-
tion (RFCA) of ventricular arrhythmias using a remote
magnetic navigation (RMN) system?
Methods: RMN and an electroanatomical mapping system
were used for mapping and RFCA in 110 patients (mean
age 56 years) with left ventricular tachycardia or frequent
ventricular premature beats arising in the left ventricle. A
3.5-mm irrigated-tip catheter with embedded magnets was
used. All patients underwent endocardial mapping and 33%
also underwent epicardial mapping using a subxyphoid
approach. Outcomes were compared to a control group of
92 patients who underwent manual mapping/ablation.
Results: RFCA by RMN was successful acutely in 86% of
patients. In the other 14%, a successful outcome was
achieved after crossover to the manual approach. RMN was
associated with a 24-minute prolongation in procedure time
and a 9-minute shortening in fluoroscopy time. Long-term
freedom from recurrent ventricular arrhythmias did not dif-
fer significantly between the RMN and control groups: 85%
at a mean 12-month follow-up in the RMN group, and 86%
at a mean 18-month follow-up in the control group. 
Conclusions: RFCA of ventricular arrhythmias using RMN is
as effective as the standard manual approach.
Perspective: In prior studies of RFCA of ventricular arrhyth-
mias by RMN, acute efficacy was only ~50%. The higher
acute success rate in the present study is attributable to the
use of an irrigated-tip catheter. They are more likely than
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measured in automated fashion, and this relationship was
used to determine the QT interval at HRs of 120 and 100
bpm. Deaths were identified by review of hospital records
and the Social Security Death Index.
Results: Mortality at a mean follow-up of 7.6 years was 7.6%.
After adjusting for multiple other risk factors including ejec-
tion fraction, a QT interval >316 ms during recovery at HR
of 120 bpm was an independent predictor of death (hazard
ratio, 1.46).
Conclusions: An abnormal QT interval at HR of 120 bpm
during recovery from exercise is an independent predictor of
mortality.
Perspective: Quantitating QT dynamics by determining the
QT interval at HR of 500 ms (120 bpm) avoids the limita-
tions associated with use of the Bazett formula, particularly its
unreliability at high HRs. Although the causes of death were
not determined in this study, the predictive value of a repolar-
ization abnormality induced by exercise presumably is related
to an increased risk of malignant ventricular arrhythmias.  
Summary written by: Fred Morady, MD
Birth Weight Is a Significant Risk Factor for
Incident Atrial Fibrillation
Conen D, Tedrow UB, Cook NR, Buring JE, Albert CM.
Circulation 2010;122:764–770.
Study Question: Do early life factors such as birth weight
(BW) contribute to atrial fibrillation (AF) later in life?
Methods: A group of 27,982 women older than 45 years and
free of cardiovascular disease and AF were followed for a
median of 14.5 years. The relationship between BW and
new-onset AF was analyzed.
Results: BWs were 3.2-3.9 kg in 51% of women, 2.5-3.2 kg
in 26%, <2.5 kg in 11%, 3.9-4.5 kg in 10%, and >4.5 kg in
3%. New-onset AF occurred in 735 women during follow-
up. After adjusting for multiple potential confounders
including body mass index, hypertension, and diabetes,
there was a significant relationship between BW and the
incidence of a first episode of AF. Compared to a BW <2.5
kg, a BW of 2.5-3.2 kg was associated with a 31% higher
risk of AF and a BW >4.5 kg with a 63% higher risk of AF.
When height at study entry or maximum body weight
between the ages of 18 and 30 years also was accounted for,
there no longer was a significant relationship between BW
and AF.
Conclusions: BW is associated with the risk of AF in women.
Weaknesses of the study include the small number of
patients and limited long-term data. We await further con-
firmatory studies from other sites with more robust groups
of patients prior to application of this approach in more
conventional-risk patients.  
Summary written by: Himanshu J. Patel, MD
The Effect of Warfarin Therapy on Endoleak
Development After Endovascular Aneurysm Repair
(EVAR) of the Abdominal Aorta
Bobadilla JL, Hoch JR, Leverson GE, Tefera G.
J Vasc Surg 2010;52:267–271.
Study Question: What is the effect of prolonged anticoagula-
tion with warfarin on the rate of endoleaks in patients
undergoing endovascular abdominal aortic aneurysm repair
(EVAR)?  
Methods: This was a prospective cohort study of 127 consec-
utive patients on warfarin or antiplatelet therapy (aspirin or
clopidogrel) who had EVAR at a single institution from
January 2000 to January 2007. The predefined endpoints
were time to endoleak, persistence of endoleak requiring
intervention, and aneurysm sac volumetric expansion.
Results: Of the 127 patients, 103 were treated with antiplatelet
therapy and 24 with warfarin after EVAR. Mean follow-up
was 2.14 years. There was no significance in the demographic
characteristics or risk factors in the two groups except patients
in the warfarin group were more likely to have coronary dis-
ease (p = 0.006). The mean size of aneurysms treated was 5.9
cm. The international normalized ratio target range for
patients on warfarin was between 2.0 and 3.0. There were 38
endoleaks (29.9%) identified, significantly more endoleaks in
the warfarin (54.2%) than the antiplatelet group (24.3%, p =
0.004) after EVAR, but no significant difference in the type
of endoleak that occurred. There were also significant differ-
ences in the aneurysm sac sizes, with the warfarin patients
having an increase of 16% (29.3 cm3) on volumetric computed
tomography angiography, whereas the antiplatelet group
aneurysm sacs decreased by 9.7% (18.9 cm3) over the follow-
up period (p = 0.04).
Conclusions: Anticoagulation with warfarin appears to be
associated with more endoleaks after EVAR compared to
antiplatelet agents alone. This increase was associated with a
significant increase in sac volumes in patients on warfarin
compared with those on antiplatelet agents.
Perspective: It is interesting that the rate of resolution of type
II endoleaks was ~45% and similar between groups. This
nonirrigated catheters to create adequate lesions in areas of
low flow, such as the pericardial space or in left ventricular
scars.   
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Endovascular Repair of Aortic Arch Lesions in
High-Risk Patients or After Previous Aortic
Surgery: Midterm Results 
Canaud L, Hireche K, Berthet JP, Branchereau P, Marty-Ané C, 
Alric P.
J Thorac Cardiovasc Surg 2010;140:52–58.
Study Question: What are the midterm results after thoracic
aortic endovascular repair of the aortic arch in high-risk
patients or after previous aortic surgery?
Methods: From 1998 to November 2008, 57 stent grafts were
inserted in 44 patients for aortic arch repair defined as the
segment of aorta from the ascending position and extending
to the left subclavian artery. The pathologic indication for
intervention included degenerative aneurysms (19), traumatic
transections of the aorta (12), complicated aortic dissection
(8), postcoarctectomy aortic pseudoaneuryms (4), and pene-
trating atheromatous aortic ulcer (1). Endovascular repair was
performed in the emergency setting in 27% of patients, and 34
of the 44 patients underwent hybrid technique with debranch-
ing of the arch vessels with endovascular therapy. Treatment
zones included zone 0 (i.e., including areas of the aorta involv-
ing the innominate artery and proximal, n = 6), zone 1 (just
distal to the innominate artery and extending to encompass
the left carotid origin, n = 4) and zone 2 (extending from the
distal aspect of the left carotid artery to encompass the origin
of the left subclavian artery, n = 24).
Results: The technical success rates for the procedure were
100% in zones 0 and 1, and 97% in zone 2 patients. Thirty-
day mortality was 20% and survival at 29 months was 70%.
Stroke was seen in 6.8% of patients and paraplegia in 4.5% of
the patients. Endoleak was seen in 15.9% of patients and one
stent graft was noted to collapse 20 days after repair of a trau-
matic aortic transection.
Conclusions: Hybrid arch reconstruction involving arch
debranching with endovascular repair is considered suitable
in high-risk patients, with encouraging midterm results.
Perspective: While these study results are interesting, they do
highlight several issues. Isolated arch aortic pathology is dif-
ficult to treat either with an open or endovascular approach.
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suggests that the effect of anticoagulation after EVAR may
not interfere with subsequent sac thrombosis. I would hesi-
tate to hold warfarin after EVAR in patients with serious
indications for anticoagulation, especially since the authors
noted no difference in the number of abdominal aortic
aneurysm ruptures or graft explants between groups.
Summary written by: John E. Rectenwald, MD
Congenital Heart Disease
Predictors of Pregnancy Complications in Women
With Congenital Heart Disease 
Drenthen W, Boersma E, Balci A, et al.
Eur Heart J 2010;31:2124–2132.
Study Question: What are the pregnancy outcomes of women
with congenital heart disease?
Methods: A retrospective review of 1,302 pregnancies in
1,802 women with congenital heart disease was performed.
The Dutch CONCOR registry and the database from an
additional tertiary center were used. The Cardiac Disease in
Pregnancy (CARPREG) risk score was calculated for each
patient, and a modified risk score was developed.
Results: The most common maternal cardiac complication
was arrhythmia (4.7%), followed by heart failure (1.6%). On
multivariate analysis, factors associated with maternal com-
plications included cyanotic congenital heart disease, use of
cardiac medications, left heart obstruction, mechanical valve
replacement, and atrioventricular valve regurgitation greater
than moderate. Maternal hypertensive complications
occurred in 12.2%, while common neonatal complications
included small for gestational age (14%), prematurity (12%),
and mortality (4%). Adverse neonatal outcomes were pre-
dicted by presence of maternal cyanotic disease, mechanical
valve replacement, maternal smoking, multiple gestation,
and maternal use of cardiac medications. 
Conclusions: Cardiac, obstetric, and neonatal complications
are frequently encountered in women with congenital heart
disease. New risk factors identified included mechanical
valve replacement and atrioventricular valve regurgitation.
Perspective: Although this study included a large number of
patients, certain subgroups were small, particularly patients
with mechanical valves (n = 4), all of whom had complica-
tions. Applying this risk score, a patient with only a
mechanical valve as a risk factor would rate a 70% complica-
tion risk. Although mechanical valves certainly propose a
risk, particularly because of the challenges of anticoagulation,
further study with larger patient numbers will be required to
better understand the risks with mechanical valves.  
Summary written by: Timothy B. Cotts, MD
General Cardiology
Long-Term Effects of Spinal Cord Stimulation on
Angina Symptoms and Quality of Life in Patients
With Refractory Angina Pectoris—Results From
the European Angina Registry Link Study (EARL) 
Andréll P, Yu W, Gersbach P, et al.
Heart 2010;96:1132–1136. 
Study Question: What is the long-term effect of spinal cord
stimulation (SCS) on angina symptoms and quality of life in
patients with refractory angina pectoris?
Methods: During 2003–2005, all patients with refractory
angina referred for SCS treatment at 10 European centers
were consecutively included in the European registry for
refractory angina (European Angina Registry Link, EARL), a
prospective, 3-year follow-up study. In the present study, the
SCS-treated patients were followed up regarding angina
symptoms, and quality of life was assessed. Refractory angina
was defined as severe angina due to coronary artery disease
resistant to conventional pharmacological therapy and/or
revascularization.
Results: After exclusions, 121 patients were implanted; follow-
up was 12.1 months. Average age was 68 years, 78% were
men; 98% were angina Canadian Cardiovascular Society
(CCS) class 3 or 4 and 72% had more than seven angina
attacks per week; 74% had undergone coronary artery bypass
grafting and 55% percutaneous coronary intervention; 15%
had a left ventricular ejection fraction <40%. The implanted
patients reported fewer angina attacks (p < 0.0001), reduced
short-acting nitrate consumption (p < 0.0001), and improved
CCS class (p < 0.0001). Furthermore, quality of life was sig-
nificantly improved; 5.8% of the implanted patients died
within 1 year of follow-up. 
Conclusions: SCS treatment is associated with symptom relief
and improved quality of life in patients with refractory
angina pectoris suffering from severe coronary artery disease.
Perspective: The prevalence and medical costs of refractory
angina are high. Because of the nonspecificity of chest dis-
comfort and varying causes of ischemic chest pain, it is
difficult to assess the efficacy of new treatment modalities.
When patients are drug refractory and not considered candi-
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women. A significant gender gap in presentation time
remains.
Perspective: These data suggest that national awareness cam-
paigns do not translate into meaningful reductions in time
from onset of cardiac symptoms to presentation. However,
further analyses of these data are likely to provide more
detailed and clinically useful information on specific factors
that may relate to delay in presentation and could be used in
future educational interventions.  
Summary written by: Elizabeth Jackson, MD
Biomarkers in Acute Myocardial Infarction
Chan D, Ng LL.
BMC Medicine 2010;8:34.
Perspective: The following are 10 points to remember about
biomarkers in acute myocardial infarction (MI):
1: A good biomarker is easily measured, and can be used as a
sensitive and specific surrogate marker for disease and its
severity. Cardiac troponin levels have revolutionized risk strat-
ification and management of patients presenting with chest
pain, although there is a several hour time delay between
symptoms and elevation in serum levels.
2: Copeptin may be useful in ruling out MI. At the time of
presentation, a copeptin level <14 pg/ml along with a troponin
T level <0.01 has been shown to rule out MI with a negative
predictive value of 99.7%, thus potentially obviating the need
for prolonged monitoring and serial blood tests.
3: Heart-type fatty acid binding protein (H-FABP) is rap-
idly released early in the setting of myocardial necrosis.
While use of this marker has not been shown to be useful
for earlier diagnosis of MI, elevated levels may be useful in
predicting prognosis following acute coronary syndrome
(ACS).
4: Elevated markers of myocardial biomechanical stress such
as B-type natriuretic peptide (BNP)/NT-proBNP and mid
regional pro-atrial natriuretic peptide (MRproANP) have
been shown to be predictive of death and heart failure fol-
lowing ACS presentation.  
5: Growth differentiation factor (GDF) 15, ST2, and
endothelin-1 have been shown to be elevated in the setting
of myocardial stress, and elevated levels are associated with
adverse outcomes. GDF-15 levels may improve selection of
patients for an early invasive strategy.
6: A marker of neurohormonal activation, adrenomedullin,
is associated with death and heart failure following acute
dates for revascularization, I prefer cardiac rehab and external
counterpulsation, which have been demonstrated to reduce
ischemia and angina, and improve quality of life, with the
potential to reduce cardiovascular events.  
Summary written by: Melvyn Rubenfire, MD
Gender Differences in Time to Presentation for
Myocardial Infarction Before and After a National
Women’s Cardiovascular Awareness Campaign: A
Temporal Analysis From the Can Rapid Risk
Stratification of Unstable Angina Patients Suppress
Adverse Outcomes With Early Implementation
(CRUSADE) and the National Cardiovascular Data
Registry Acute Coronary Treatment and
Intervention Outcomes Network-Get With the
Guidelines (NCDR ACTION Registry–GWTG) 
Diercks DB, Owen KP, Kontos MC, et al.
Am Heart J 2010;160:80–87. 
Study Question: Does a national awareness campaign regarding
heart disease result in reducing time from symptoms to pres-
entation for acute coronary syndrome among women?
Methods: Data from two large-scale registries were used for
this analysis. Patients with non-ST-elevation myocardial
infarction (NSTEMI) from the CRUSADE and NCDR
ACTION Registry–GWTG were grouped into three time
periods (preintervention 2002-2003, intermediate 2004-2005,
and post-intervention 2006-2007), according to timing of a
national American Heart Association and National Heart,
Lung, and Blood Institute awareness campaign for women.
Patients enrolled in the CRUSADE registry between January
1, 2001 and December 31, 2006, from 568 sites, and patients
enrolled in the NCDR ACTION Registry from January 1,
2007 to December 31, 2007, were included.
Results: A total of 125,161 patients were included; 40.1%
were women. The median time from symptom onset to
presentation was longer in women compared to men (3 vs.
2.8 hours, p < 0.0001). No measureable reduction in time
from symptom onset to presentation over the period of time
in which the national awareness campaign was conducted
was observed. After adjustment for covariates, women ages
40-60 years had a 3.46% longer time to presentation com-
pared to men (95% confidence interval, 1.06-5.92). 
Conclusions: No reduction in time from symptom onset to
hospital presentation for MI in patients has been observed
since the initiation of national awareness campaigns for
JACC, Vol. 56, No. 15, 2010
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MI, information that is additive to NT-proBNP.
7: Markers of inflammatory activity, such as C-reactive pro-
tein, pentraxin 3, myeloperoxidase, and pregnancy-
associated plasma protein A, have been shown to be predic-
tive of cardiovascular events; however, use of these markers
for predicting adverse events following MI is less clear.
8: Matrix metalloproteinases (MMP 2 and 9) and MMP
inhibitors may affect left ventricular remodeling following
MI, and elevated levels have been associated with adverse
prognosis following MI. 
9: Although many biomarkers have been studied in clinical
trials, the specific mechanism(s) by which the biomarker is
generated and the role of the marker in cardiovascular dis-
ease remains unclear. Increased understanding of the
biochemistry and pathophysiology of these biomarkers will
aid in their application.
10: Most currently proposed biomarkers have not gained
widespread acceptance for use in clinical management of
patients (except cardiac troponins). Additional randomized
clinical trials based on the use of biomarkers to tailor treat-
ment are needed.
Summary written by: Daniel T. Eitzman, MD
Heart Failure/Transplant
Cardiac Surgery Late After Heart Transplantation:
A Safe and Effective Treatment Option
Goerler H, Simon A, Warnecke G, et al.
J Thorac Cardiovasc Surg 2010;140:433–439.
Study Question: What is the mortality associated with cardiac
operations in patients who have had a prior cardiac transplant?
Methods: A prospectively collected, single-center, cardiac
transplant database of 867 patients was retrospectively
reviewed (1983-2008), and mortality for subjects undergoing
late (>30 days after cardiac transplant) nonretransplant car-
diac operations was calculated using Kaplan-Meier methods.
These results were compared with subjects undergoing
repeat cardiac transplant.
Results: There were 44 nontransplant cardiac operations a
mean of 8.4 ± 5 years after initial transplant. Mean follow-
up was 5.8 ± 4.7 years. Surgeries included coronary artery
bypass grafting (CABG) for coronary disease and/or vascu-
lopathy (n = 19), TVR for severe tricuspid regurgitation (n =
17), multivalve intervention for endocarditis (n = 1), MVR
for mitral regurgitation (n = 1), aortic root replacement for
dissection at suture line (n = 3), right atrial thrombectomy (n
= 1), and CABG plus TVR (n = 2). There were four addi-
tional reoperations (root replacement for chronic aortic
dissection, MVR, a combined MVR plus TVR, isolated
AVR). Early mortality (≤30 days) was 4.5% (2/44) and there
were 20 late deaths. Actuarial survival at 1, 3, and 5 years
was 84%, 72%, and 64%, respectively. Actuarial survival in
those undergoing repeat cardiac transplant (n = 20) for the
same time points was 70%, 70%, and 70%, respectively.
Conclusions: Nonretransplant surgery for cardiac vasculopathy
and valvular disease is safe and effective.
Perspective: This study shows the rarity with which cardiac
operations are undertaken in cardiac transplant patients (5%).
Early mortality appears acceptable, but power is limited. In
this group of subjects with likely underlying renal insufficiency
and prior sternotomy, it would have been interesting to learn
about important postoperative morbidities such as renal fail-
ure, bleeding, and length of stay.  
Summary written by: Jennifer Cowger, MD
Myocardial Fibrosis as an Early Manifestation of
Hypertrophic Cardiomyopathy
Ho CY, Lopez B, Coelho-Filho OR, et al.
N Engl J Med 2010;363:552–563.
Study Question: Is there evidence of abnormal collagen metabo-
lism in patients with early hypertrophic cardiomyopathy
(HCM)? 
Methods: This was a blinded prospective study comparing
results from cardiac imaging and serum markers of cardiac
wall stress, collagen synthesis (C-terminal propeptide of type
I procollagen [PICP]) and collagen degradation (C-terminal
telopeptide of type I collagen [CITP]) in subjects with HCM
gene mutations and overt HCM (n = 38), HCM gene muta-
tions without HCM (n = 39), and healthy family controls (n
= 30) without gene mutation or cardiac pathology.
Results: PICP levels were significantly higher in mutation
carriers without HCM (108 ± 5 μg/L) and in those with
HCM (139 ± 11 μg/L) than in controls (82 ± 3 μg/L, both
p < 0.001 for comparison with control). Late gadolinium
enhancement on magnetic resonance imaging did not corre-
late with PICP levels. In family members with normal left
ventricular thickness, the adjusted odds of carrying an HCM
mutation increased 50% for each 10 μg/L increase in PICP.
Serum markers of collagen degradation and wall stress did
not differ between groups. But, the PICP/CITP ratio was
significantly higher in those with overt HCM than in those
without overt HCM or controls, suggesting that collagen
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synthesis is greater than degradation in overt HCM.
Conclusions: PICP levels are elevated in HCM gene-positive
patients without overt disease.
Perspective: The authors provided two important insights into
the HCM disease. First, they demonstrated increased collagen
synthesis (PICP) in carriers of the HCM mutation without an
overt HCM phenotype. This may help guide monitoring of
at-risk family members beyond that of imaging studies.
Second, the finding of an elevated PICP/CITP ratio in those
with overt disease helps elucidate an understanding of HCM
progression in genotypic carriers—collagen synthesis surpasses
degradation, leading to unchecked fibrosis.
Summary written by: Jennifer Cowger, MD
Interventional Cardiology
Short-Term Effects of Transcatheter Aortic Valve
Implantation on Neurohormonal Activation, Quality
of Life and 6-Minute Walk Test in Severe and
Symptomatic Aortic Stenosis
Gotzmann M, Hehen T, Germing A, et al.
Heart 2010;96:1102–1106.
Study Question: What is the impact of transcatheter aortic
valve implantation (TAVI) on B-type natriuretic peptide
(BNP) levels and quality of life?
Methods: The authors assessed quality of life using the
Minnesota Living with Heart Failure questionnaire
(MLHFQ), 6-minute walk test, and measured BNP at
baseline and 30 days after TAVI. All patients also under-
went echocardiography.
Results: The study cohort was comprised of 44 patients. The
average age was 79.1 years, and one-half of the patients were
women. Successful TAVI was followed by an increase in
systolic blood pressure, a decrease in the transaortic gradi-
ent, and a reduction in left ventricular end-diastolic
pressure. At the 30-day follow-up, there was a significant
improvement in quality of life (MLHFQ score 44 ± 19 at
baseline vs. 28 ± 17 at follow-up, p < 0.001) and an
increased 6-minute walk distance (baseline 204 ± 103 m vs.
266 ± 123 m, p < 0.001). There was a significant reduction
in BNP levels (baseline 725 vs. 423 pg/ml, p = 0.005).
Conclusions: TAVI is associated with significant improve-
ment in quality of life.
Perspective: Percutaneous aortic valve placement has emerged
as a viable option for patients who are deemed poor surgical
candidates. The authors demonstrated improvement in all
parameters studied, adding to the growing data supporting
TAVI. As the technology matures and the procedure is per-
formed in patients who are less sick, more studies like this will
help define the role of TAVI in patients with aortic stenosis.
Summary written by: Hitinder S. Gurm, MBBS
Prevention/Vascular
Pressor Responses to Antihypertensive Drug Types
Alderman MH, Cohen HW, Sealey JE, Laragh JH.
Am J Hypertens 2010;23:1031–1037.
Study Question: What are the blood pressure (BP) responses
to particular antihypertensive drug monotherapies and their
relationship to baseline ambulatory plasma renin activity
(PRA) levels in hypertensive patients? 
Methods: Systolic blood pressure (SBP) response was evaluated
among 945 participants with no prior treatment who were
given either a diuretic or calcium-channel blocker (natriuretic
antivolume V drugs, n = 537) or a beta-blocker or
angiotensin-converting enzyme (ACE) inhibitor (antirenin R
drugs, n = 408). PRA was categorized by low, middle, and
high tertiles (L, M, and H). SBP rise ≥10 mm Hg was con-
sidered pressor response.
Results: More pressor responses occurred with R than V drugs
(11% vs. 5%, p = 0.001). L, M, and H renin tertiles had simi-
lar frequencies with V drugs (6, 4, and 6%), but low and
middle tertiles given R had greater pressor frequencies (17% p
= 0.003 vs. V and 10% p = 0.02 vs. V). Treatment SBP ≥160
mm Hg occurred more frequently with R than V drugs (19%
vs. 13%; p = 0.007); moreover, in the lowest renin tertile, 35%
R vs. 13% V (p = 0.001) had SBP ≥160 mm Hg. Treatment
SBP <130 mm Hg was more frequent in V patients in the
lowest tertile (18% vs. 5%; p = 0.003), and in R patients in the
highest tertile (26% vs. 12%, p = 0.002). 
Conclusions: Pressor responses to antihypertensive monother-
apy occur sufficiently frequently to be of concern, especially in
lower renin patients given a beta-blocker or ACE inhibitor. 
Perspective: The data in this study indicate that patients with
low PRA values are at the highest risk of a pressor response
when prescribed an antirenin drug. However, it is important
to recognize that ≥10 mm Hg increases in systolic pressure
can occur with any antihypertensive drug, and at any level of
PRA. The clinical implications of these retrospective findings
need to be ascertained in a prospective study.
Summary written by: Debabrata Mukherjee, MD
JACC, Vol. 56, No. 15, 2010
October 5, 2010:1169–76
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A Longitudinal Study of Serum Lipoproteins in
Relation to Endogenous Reproductive Hormones
During the Menstrual Cycle: Findings From the
BioCycle Study
Mumford SL, Schisterman EF, Siega-Riz AM, et al.
J Clin Endocrinol Metab 2010;Jun 9:[Epub ahead of print].
Study Question: Are endogenous estrogens associated with lev-
els of serum lipoproteins across the menstrual cycle? 
Methods: This was a prospective cohort study of regularly men-
struating women enrolled at the University of Buffalo from
2005 through 2007. Timing of visits was based on fertility
monitors. Estradiol, progesterone, LH, and FSH were meas-
ured at each clinic visit. Primary outcomes of interest were
serum levels of total cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) choles-
terol, and triglycerides, which were measured up to eight
times per menstrual cycle for up to two cycles. 
Results: A total of 259 women, ages 18-44 years (mean 27.3
years), were included. The majority of women were single,
nulliparous, normal weight, white women. This cohort was
also highly physically active and had obtained some degree
of post-secondary education. Total cholesterol and LDL
cholesterol were highest during the follicular phase and low-
est during the luteal phase (p < 0.001). HDL levels were
highest around the time of ovulation (p < 0.001). More
women were classified above the desirable range for LDL
(≥130 mg/dl) or total cholesterol (≥200 mg/dl) when lipids
were measured during the follicular phase. Estradiol was
positively associated with HDL and inversely associated
with total and LDL cholesterol. Estradiol was also inversely
correlated with serum triglycerides. 
Conclusions: Endogenous estrogen appears to have beneficial
effects on serum lipids. Because lipoprotein cholesterol lev-
els vary across the menstrual cycle, cyclic variations in
lipoprotein levels may need to be considered in the design
and interpretation of studies, which include reproductive-
age women, and in the clinical management of women’s
cholesterol. 
Perspective: This study provides some interesting and
thought-provoking data. The important question from a
clinical perspective would be the variation in numbers of
women recommended for pharmacologic therapy due to
timing of lipid measurements in relation to the menstrual
cycle. A small variation in clinically treatable levels suggests
less of a clinical impact to these findings.
Summary written by: Elizabeth A. Jackson, MD
Common Genetic Determinants of Vitamin D
Insufficiency: A Genome-Wide Association Study
Wang TJ, Zhang F, Richards JB, et al.
Lancet 2010:376:180–188.
Study Question: Are common sequence variants associated
with circulating levels of vitamin D?
Methods: A genome-wide association study of 25-hydroxyvita-
min D concentrations in 33,996 individuals of European
descent from 15 cohorts was performed. Five cohorts were
designated as discovery cohorts (n = 16,125), five as in-silico
replication cohorts (n = 9,367), and five as de-novo replica-
tion cohorts (n = 8,504). Vitamin D insufficiency was defined
as concentrations lower than 75 nmol/L or 50 nmol/L.
Genotype scores were constructed for confirmed variants. 
Results: Variants at three loci were associated with 25-
hydroxyvitamin D concentrations and confirmed in
replication cohorts: 4p12 (overall p = 1.9 x 10–109 for
rs2282679, in GC); 11q12 (p = 2.1 x 10–27 for rs12785878,
near DHCR7); and 11p15 (p = 3.3 x 10–20 for rs10741657,
near CYP2R1). Variants at an additional locus (20q13,
CYP24A1) were genome-wide significant in the pooled
sample (p = 6.0 x 10–10 for rs6013897). Participants with a
genotype score in the highest quartile were at increased risk
of having 25-hydroxyvitamin D concentrations lower than
75 nmol/L or lower than 50 nmol/L compared with those
in the lowest quartile.
Conclusions: Variants near genes involved in cholesterol syn-
thesis, hydroxylation, and vitamin D transport affect
vitamin D status.
Perspective: Many disorders have been associated with low
levels of vitamin D, including cardiovascular disease. Diet
and ultraviolet light exposure are minor contributors to vari-
ation in vitamin D concentrations between individuals
(~25%). Family and twin studies suggest a high heritability
index (>50%) for vitamin D levels. The current study indi-
cates that common variants, near genes with high biological
plausibility, are important contributors to vitamin D status.
Whether these intriguing results will apply to a more diverse
population and be useful for risk stratification/screening
strategies will require further study.
Summary written by: Daniel T. Eitzman, MD
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